Both sides fear undue influence on independent review of US FDA CTP

The tobacco industry has little faith that the upcoming external review of the Center for Tobacco Products (CTP) announced by US Food and Drug Administration (FDA) commissioner Robert Califf will help fix faults in the agency’s regulation of new tobacco and alternative products.

Industry representatives say the review, to be carried out by the agency’s partner organisation Reagan-Udall Foundation, is being launched at a time when delays and back-tracking in handling the pre-market tobacco application process (PMTA) for alternative tobacco products are all too evident and have already produced wide damage.